Castle Biosciences (CSTL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.07
- Estimate
- -$0.41
- Surprise
- +82.8%
- Revenue (period 2026-06-30)
- $103.5M
- Score today
- 6.2/10
Revenue source: xbrl.
How the report landed
Castle Biosciences (CSTL) reported a narrower loss than forecast — diluted EPS of -$0.07 against the -$0.41 estimate (a 82.8% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CSTL Sell at 6.2/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +82.8% surprise compares with a +61.9% four-quarter average. Next scheduled report: 2026-11-02.
What argues against it
- Quality below floor (3.6 < 4.0)
- Reward/Risk 0.8:1 at current price — below 1.5:1 minimum
- Insider activity: 0.40%=heavy
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $34.20
- Price target
- $38.28
- Stop
- $31.81
- Upside to target
- +11.9%
- Reward-to-risk
- 0.8:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
CSTL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $1.04B
- P/E (fwd)
- -34.6
- 52-week range
- $17.72–$44.28
- Off 52-week high
- 22.8%
- RSI (14)
- 65
- Volume vs avg
- 1.10×
- Score today
- 6.2/10